Cure & cancer: cannabis molecule blend research

By Flora Southey contact

- Last updated on GMT

iStock/cyano66
iStock/cyano66

Related tags: Cannabis, Pharmacology, Chemotherapy

Cure Pharmaceutical has entered into a strategic collaboration to test and develop potential cancer therapeutics utilising a blend of the cannabis plant-derived terpenes. 

The California, US-based company, together with cannabinoid therapy developer CannaKids, is collaborating with Israel-based Technion Research and Development Foundation, to test terpene blend-based treatments on certain subtypes of cancer.

The firm is predominantly interested in amalgamating terpene molecules, which it says is superior to isolate versions.  

“It is believed that the combination of these molecules are more effective than creating an isolate,” ​a Cure Pharma spokesperson told in-PharmaTechnologist.

“By placing scientific rigor behind the testing of the potential cannabinoid cancer treatments we will be able to identify which molecule combinations are more effective,” ​said the spokesperson.

“The results of the research will be used to predict how to match a cancer subtype with an effective cannabis extract in order to optimise treatment efficacy,” ​the firm told us.

Cure Pharma will oversee the fractionations of cannabinoids and terpene blends, and CannaKids will provide patient data.

“CannaKids brings a plethora of retrospective patient data and formulation information that will be extremely useful in developing the formulas to be tested in Israel,” ​the spokesperson told us.

Antitumour effects

According to Cure Pharma, preclinical evidence​ indicates that cannabinoids have antitumour effects.

“Several studies have demonstrated the use of cannabinoids in being able to regress different cancer types,” ​said the spokesperson.

Cure CEO Rob Davidson said the Technion team aims to provide further evidence of cannabinoids antitumour characteristics.

“The Technion team aims to clarify the antitumor effects of phystocannabinoids and terpenes on various cancer-driving mutations and pathways, as well as further elucidating the mechanism of the cannabinoid-mediated antitumor effects,” ​he said.

“This will allow not only the identification of new drug candidates but also will create the ability to optimize cannabis treatment options for patients,” ​said Davidson.

Cure aims to take promising drug candidates through the regulatory requirements, and to the market.

Related news

Related products

SQ-USP-Brochure-Thumb-AP-CC

NEW…sugarcane derived USP Squalane from Aprinnova

APRINNOVA – A joint venture of AMYRIS and NIKKOL Group | 26-Feb-2018 | Product Brochure

To date, topical formulation chemists have been restricted to using Squalane derived from the harvesting of shark livers. Neossance Squalane USP, derived...

TCC TB – a new filler for direct compression

TCC TB – a new filler for direct compression

Jungbunzlauer | 09-Oct-2017 | Technical / White Paper

TCC TB is a tricalcium citrate tetrahydrate designed to function as a direct compression excipient. It combines exceptional compression characteristics,...

Related suppliers